How is comprehensive genomic profiling different from single-gene ("hot spot") testing for solid tumors?
Single-gene testing identifies only one or two classes of genomic alterations. Comprehensive genomic profiling (CGP) approach identifies four classes of genomic alterations: base substitutions, insertions and deletions/indels, copy number alterations, and rearrangements.
Who is eligible for the tests?
Any patient with a solid tumor, hematologic malignancy, or sarcoma is eligible for our tests.
Whom can I contact with additional questions?